IL319011A - Triazinone derivatives as nlrp3 inhibitors - Google Patents

Triazinone derivatives as nlrp3 inhibitors

Info

Publication number
IL319011A
IL319011A IL319011A IL31901125A IL319011A IL 319011 A IL319011 A IL 319011A IL 319011 A IL319011 A IL 319011A IL 31901125 A IL31901125 A IL 31901125A IL 319011 A IL319011 A IL 319011A
Authority
IL
Israel
Prior art keywords
triazinone derivatives
nlrp3 inhibitors
nlrp3
inhibitors
triazinone
Prior art date
Application number
IL319011A
Other languages
Hebrew (he)
Inventor
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Jonathan Martin Shannon
Sandra Steiner
Andreas Michael Tosstorff
Original Assignee
Hoffmann La Roche
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Jonathan Martin Shannon
Sandra Steiner
Andreas Michael Tosstorff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Lea Aurelie Bouche, Wolfgang Guba, Georg Jaeschke, Stefanie Katharina Mesch, Jonathan Martin Shannon, Sandra Steiner, Andreas Michael Tosstorff filed Critical Hoffmann La Roche
Publication of IL319011A publication Critical patent/IL319011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL319011A 2022-11-09 2023-11-07 Triazinone derivatives as nlrp3 inhibitors IL319011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22206271 2022-11-09
PCT/EP2023/080895 WO2024099992A1 (en) 2022-11-09 2023-11-07 Triazinone derivatives as nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
IL319011A true IL319011A (en) 2025-04-01

Family

ID=84330531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319011A IL319011A (en) 2022-11-09 2023-11-07 Triazinone derivatives as nlrp3 inhibitors

Country Status (15)

Country Link
EP (1) EP4615841A1 (en)
JP (1) JP2025539252A (en)
KR (1) KR20250103639A (en)
CN (1) CN120187721A (en)
AR (1) AR130984A1 (en)
AU (1) AU2023376398A1 (en)
CA (1) CA3268380A1 (en)
CL (1) CL2025001372A1 (en)
CO (1) CO2025005518A2 (en)
CR (1) CR20250185A (en)
IL (1) IL319011A (en)
MX (1) MX2025004959A (en)
PE (1) PE20251696A1 (en)
TW (1) TW202434581A (en)
WO (1) WO2024099992A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
JP2026509587A (en) * 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 Triazine compounds and their uses
TW202545527A (en) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3 and glp-1a combination therapies
WO2025261430A1 (en) * 2024-06-21 2025-12-26 成都赜灵生物医药科技有限公司 Benzothiophene deuterated compound and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (en) * 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
WO2021219784A1 (en) * 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds

Also Published As

Publication number Publication date
WO2024099992A1 (en) 2024-05-16
MX2025004959A (en) 2025-06-02
JP2025539252A (en) 2025-12-04
PE20251696A1 (en) 2025-07-02
TW202434581A (en) 2024-09-01
CO2025005518A2 (en) 2025-05-19
AR130984A1 (en) 2025-02-05
AU2023376398A1 (en) 2025-02-13
KR20250103639A (en) 2025-07-07
CL2025001372A1 (en) 2025-06-23
CA3268380A1 (en) 2024-05-16
CR20250185A (en) 2025-06-10
CN120187721A (en) 2025-06-20
EP4615841A1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
IL319009A (en) Triazinone derivatives as nlrp3 inhibitors
HUE071498T2 (en) Nlrp3 inhibitors
EP4077328A4 (en) Pyridopyrimidine derivatives as kras inhibitors
IL287042A (en) Nlrp3 inflammasome inhibitors
SI4363406T1 (en) Nlrp3 inflammasome inhibitors
IL318258A (en) Novel nlrp3 inflammasome inhibitors
IL310403A (en) Substituted pyridine derivatives as sarm1 inhibitors
IL309013A (en) Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
IL306065A (en) Uracil derivatives as trpa1 inhibitors
IL318533A (en) Nlrp3 inflammasome inhibitors
IL320747A (en) Piperidine derivatives as mettl3 inhibitors
IL314297A (en) N3-substituted uracil compounds as trpa1 inhibitors
IL308071A (en) Process for the preparation of nlrp3 inhibitors
IL301717B2 (en) Tetrazole derivatives as trpa1 inhibitors
EP4293018A4 (en) Compound serving as nlrp3 inhibitor
IL310777A (en) Substituted s-alaninate derivatives
IL315980A (en) Egfr inhibitors
IL299172B2 (en) Tetrazole derivatives as trpa1 inhibitors
PT4171563T (en) Tetrazole derivatives as trpa1 inhibitors
PT4337652T (en) Nlrp3 inhibitors
CA3273093A1 (en) Triazinone derivatives as nlrp3 inhibitors
CA3297023A1 (en) Triazine derivatives as nlrp3 inhibitors
AU2024307670A1 (en) Triazine derivatives as nlrp3 inhibitors
HK40122649A (en) Nlrp3 inhibitors
IL321066A (en) Proccesses for the preparation of an nlrp3 inhibitor